法隆制药公司获得癌症药物Bexmarilimab专利延长至2040年。 Faron Pharmaceuticals receives patent extension for cancer drug Bexmarilimab until 2040.

法隆制药公司获得了一项新的美国专利,将对其实验癌症药物Bexmarilimab的保护扩大到2040年。 Faron Pharmaceuticals has received a new US patent extending the protection for its experimental cancer drug, Bexmarilimab, until 2040. 这种药物针对某些癌症细胞,目前正在研究治疗白血病和肾上腺肿综合症等癌症。 This drug targets certain cancer cells and is being studied for treating cancers like leukemia and myelodysplastic syndrome. 专利涵盖利用Bexmarilimab用特定的细胞结构治疗癌症,有可能扩大专利的使用范围,并保护公司。 The patent covers using Bexmarilimab to treat cancers with specific cell structures, potentially expanding its use and protection for the company.